J. N. Atkins

Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer

Bernard Fisher, James J. Dignam, Birol Emir et al. · JNCI Journal of the National Cancer Institute · 1997 · 521 citations · Full text

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

Bernard Fisher, Stewart Anderson, D. Lawrence Wickerham et al. · Journal of Clinical Oncology · 1997 · 311 citations

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

Bernard Fisher, James J. Dignam, Eleftherios P. Mamounas et al. · Journal of Clinical Oncology · 1996 · 234 citations

Amelioration of vincristine neurotoxicity by glutamic acid

Don V. Jackson, H. Bradley Wells, J. N. Atkins et al. · The American Journal of Medicine · 1988 · 103 citations

Glutamic Acid, Medicine, Neuroprotection +2

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

Norman Wolmark, Greg Yothers, M J O'Connell et al. · Journal of Clinical Oncology · 2009 · 65 citations

Bevacizumab Administration, Gastrointestinal Oncology, Medicine +15